🟢 Tiziana Life Sciences is trading 18.17% up today after non-binding MOU for MS trial

Tiziana Life Sciences is trading at $0.90 (+18.17%) after disclosing a non-binding MOU supporting a planned multiple-sclerosis trial.

• The September 17, 2026 disclosure covers collaboration with KAIMRC and the Foundation for Neurologic Diseases to evaluate intranasal foralumab alongside anti-CD20 therapy.
• The collaboration expands Tiziana Life Sciences’ MS development footprint; blinded Phase 2 results remain expected in October 2026.
• Broader biotech strength is providing additional support.